We would love to hear your thoughts about our site and services, please take our survey here.
It was funny to watch those sells of exact numbers like 50k, 100k 150k and 200k shares going thro' on my level 2 portfolio. Some never showed up in the trade log - odd. That seller had definitely told their broker to sell lots at 5.5 because for ages it was firmly clamped at 5.5. Then he was doing it at 5.6 and 5.7. Then he stopped and it went up to nearly 6, then he did two more. I was selling other shares at a loss to free up the cash to buy more Hemo; I managed to get some as low as 5.4p, but also bought from 6.6p on the way down. Great day because this is worth more than the recent 7p placing price. I expect to be in the black heavily by Friday even on the shares I had earlier bought at 8p, and maybe on my 11p slightly older (but not at all long ago) ones.
It was 25p the day before the placing RNS, and the amount placed compared to market cap is small so mathematically based on the dilution it should still be at least 23.5p, ceteris paribus (all other things being equal; which in this case, they are). Of course SP is also driven by sentiment and all sorts of random and external perturbations. But, if Samuel Holdings Pty was happy to pay 21.5p for a few ÂŁmillion worth on Friday, that seems, to my mind, like a good vote of confidence that it's at least worth a little more than that.
Post placing, the dudes holding the placed shares may be tempted to sell in the 7.5 to 8 range unless we motor through that with good momentum. I don't mind at all. I hope to see 11 to 12 again if all goes well with GlobalCo partnership. Meantime we have the cleverest CEO in the world, and the best humanised mice in the world (100 days).
>>Possibly don’t want there name mentioned until they are successful in the clinical trials meaning price sensitive info.
-- exactly that. GlobalCo doesn't need or want to announce this until it's definitely come good. Seems normal to me. Optimistic.
Bit grumpy about having another paolo on the board. There's only room for one surely !!
I'd say NYCT recovers to 280 temporarily, but ends up 260 to 265p end of day. It can still exhibit some of its volatility, but now only up and down 10 to 15p. Slower decline to 230 over next 10 days.
Not long to wait with Genedrive re : antigen tests ? Mind you I don’t understand how the customers can do the “clinical evaluations”, unless the customers are major public health bodies. That must be it ??
Genedrive RNS 22nd May :
Following successful CE and IVD approvals, the Company can commence commercial sales of its Covid test kits in the UK and across the EU immediately. The Company will now begin distribution to potential customers for initial clinical evaluations, and aims to record first commercial sales in June.
(also a portable point of care covid test being developed by GDR)
https://eandt.theiet.org/content/articles/2020/06/sodium-ion-breakthrough-could-lower-environmental-impact-of-batteries/
A team from Washington State University (WSU) and Pacific Northwest National Laboratory (PNNL) reported one of the best results to date for a sodium-ion battery, with a design that holds more than 80 per cent of its charge after 1,000 cycles.
This is a key metric that makes it more appealing than other touted next-gen battery technologies, such as lithium-sulphur which starts to lose its capacity after just a few recharge cycles.
“This is a major development for sodium-ion batteries,” said Dr. Imre Gyuk, who works for the US Department of Energy. “There is great interest around the potential for replacing Li-ion batteries with Na-ion in many applications.”
Li-ion batteries have become the de facto choice for electronic gadgets, electric cars and even the mass storage of renewable electricity on the grid.
However, these batteries are made from materials such as cobalt and lithium that are rare, expensive and mostly found outside the US. In 2018, German researchers warned that shortages of these metals are expected by 2050
Sodium-ion batteries could solve the issue as they are made from cheap, abundant and sustainable sodium from the earth’s oceans or crust. Up until now, this technology has been hampered by having a lower storage capacity and short lifespans.
“Our research revealed the essential correlation between cathode structure evolution and surface interaction with the electrolyte,” Lin said. “These are the best results ever reported for a sodium-ion battery with a layered cathode, showing that this is a viable technology that can be comparable to lithium-ion batteries.”
The researchers are now working to better understand the important interaction between their electrolyte and the cathode, so they can work with different materials for improved battery design. They also want to design a battery that doesn’t use cobalt, a relatively expensive and rare metal - 60% of it comes from one African country and most of the mines are owned by RTZ; it's in ultimately shorter supply than Lithium.
>>If it gets down to under ÂŁ2 I might have another look.
- would depend on new news from now re : NYCT and re : rival antigen high-throughput tests e.g. GDR and others, and on purchasing decisions by large public healthy bodies in each governance. When NYCT says it has sold to 130 countries, it just means at least one individual or firm there has ordered at least one test. Volume orders are what counts. That's what NYCT had so far from e.g. UK due to getting their test out the blocks first, due to a good CEO decision early December on direction of firm and where to deploy its resources.
did none of you see the ghastly news hidden in the middle of that RNS that the French equivalent of public health England is stating that the nyct test is no good they are refusing to pay for all of the tests that France has bought so far for public health use and they are saying that it only targets one gene and isn't apparently accurate. Being French they are probably pretty thorough (I am impressed when I worked with French people with a university high level of science and maths education). If other governances' public health bodies take the same view and start ordering other tests this could be very negative for nyct. I sold first thing. Our day is probably done. It's been great though. To have sold that much to 130 countries is great. We were the leading antigen test vendor in a really competitive field up to now. I am looking at avct now but haven't quite decided. Low in range but GDR suppressed by a seller
I knew DDDD was due a large hike after its slumber, for the reasons the last 3 posts spelt out, utterly compelling big name partnerships. One in ten improvement is great when it comes to cancer. I bet they can improve it too. I expect a decent continuation of the rise first thing.
Struth, that's a really big short on PMO. I see that some of you post also on PMO - there seems a crossover between PMO and TLW posters. I remember there being what I considered to be a "big" short (only 4%) showing on Nanoco, a firm I have from time to time bought and sold (and currently hold, even tho' some are shorting it right now, as it has news, maybe good maybe bad, breaking to a hard deadline - 2nd June), when it had slumped from 40+p to 6p to 8p when Apple dumped it. I thought the fall looked overdone and bought a small amount. In fact it then rose to 14p, so those shorters must have been burnt badly at that time. I have come to learn from observation that a stock being shorted doesn't necessarily mean that it will fall. In fact, the shorters seem to be wrong about half the time. Never tried spread betting myself; I suspect that you could lose a lot that way quite fast, and it's better to be sure first to be able to consistently, objectively trade and hold shares themselves profitably (across the portfolio), over a long period of time (it seems a little bit easy just at the moment).
I did read elsewhere last week about the new CEO not yet being in place, and that is a short term-ve, until he's in place and showing good form. He seems to have operational exploration experience in Africa and past M&A advice/financing experience. I know about past production downgrades at Ghana and bad press late last year about debt level too; I presume that's priced in. Time will tell. It's only a small % of my stock. If Brent does stay higher and this doesn't lift from last week, that'd be quite surprising, unless a bad RNS came out. You can always have a bad RNS any time. Or, indeed, a good one. The level of shorting (8%) on this stock is quite high, but has been so for a while.
To HeresHopin : in the month of May I calculated this morning that made a return on my entire holding (in terms of capital employed across the month, weighted average as I added cash part way thro' the month) of 25%, excluding the dead money I hold forever in hope in "Eden Research" (one day it will come so good !!!) ; 18% on entire capital holding including Eden (Eden has hardly moved in spite of 2 fair RNS's this month - it's just not a very fashionable share). So not so bad, actually; I wouldn't say I'm backing losers. I wasn't holding HUR the day it tanked on the interference issue, thank goodness. I'm very wary of holding small commodities stocks for long, because of the risk of a bad RNS first thing that seems to bedevil them, especially one-mine, or one-well, outfits; but Tullow seems safer than the minnows to hold for at least a while, as my punt on rising oil prices. Chosen because low in its range on Friday, otherwise it might have been BP I went for, or even Jog (but Jog currently at a generous price, and not such a good buy; perhaps the oil authority might say yes soon to its shared pipeline proposal, but it already more or less said it would say that anyway, so that shouldn't be a big deal for Jog). If I sense TLW is near the top of the range, whatever that turns out to be, I'll be out. But I do hope for a long uplift as oil prices recover, so will try to resist any urge to sell, even when I see dip-consolidation.
A lot of people here are stirring up uncertainty and talking down this share. Which is fine - I don't mind; commentators are often (but not always) biased one way or another aren't we/they, and I own the stock as of yesterday, so I'm biased too. TLW may have a good day Monday, as Brent now almost $38; it went up after 16:30 BST stock market close yesterday, because I think of Trump’s speech about China which had measures against China in response to new security legislation that were FAR less threatening to the U.S. economy than investors had feared : and he stuck rigidly to the script his advisers had written.
I had just bought TLW late Friday afternoon as it was clearly at a low, and I had become awfully bored with waterlogged, interference-prone HUR, which I sold to switch horses with that bit of cash, because TLW was convincingly under-valued, whereas I couldn't have gotten more, if no oil price movement, than 6.8p or so from HUR no matter how long I waited, and with HUR I now find I'm always concerned of yet another rubbish RNS with some new problem. HUR will go up too, mind, if the Brent rise is sustained, but I think TLW is a much better punt right now, and safer also than gaffe-prone PANR. Time will tell.
The presence of so many negative posts for TLW actually gives me encouragement; shorters in largeish firms like TLW (it’s not small) who are panicking about a share rise, pay people to post -ve’s like that. It’s a good sign. There are a lot of shorters on this stock : https://shorttracker.co.uk/company/GB0001500809/ - now they'll be really annoyed/fearful, and there will be more -ve posts (along genuine -ve posts from people who have no stake either way, and may post +ve or -ve posts. Not everyone has a position, or a motive, and not everyone's a ramper or deramper - you can be interested in a stock, without having any financial interest in it at that time).
People are impatient and herd-like. Just look at recent cycles on stocks like itm power, cine, AMR, GDR, novacyt, and even to an extent national grid. You can profit from their irrationality, at least until a stock catches you out by moving out of its range. Hemo though, I think to be at or near bottom of range. The institutional investors about to buy ÂŁ2.7m worth at 7p 4th June must think so too. Time alone will tell.
I don't think it's good practice to "never sell at a loss". If I think a share is likely to go down, or has less upside than something else I need the cash for, I will sell at a loss. I do so often. As long as you make more than you lose, and total holdings are rising nicely, all well. If you say you never sell at a loss, as you've posted, it can leave you trapped in a failing firm.. but on this occasion your strange tactic is safe : it won't need much patience at all for hemo to be above 8p. It has good prospects. Might take a day, might take 10 days, but it'll come. The people who bought at 11 might see that again too. It really shouldn't be clamped around 7p because that's a modest sized placing and they'll do good work with the proceeds. NB the CEO's Twitter feed is excellent. He has my total confidence.
Everyone uses hemo's patent humanised mice under licence. I don't see why the modest placing should clamp it at the placing price because compared to market cap it's not a big placing and not much dilutive. So I think it's due a rise any time, which can come ahead of 4th June. So many other medical advances linked to hemo.
Correction, memory failure, I bought 16:28 today at 59.99p ! Not 56p. They'll easily be 65 within a day; perhaps more.